Theme:
Light Dark Auto
GeneralTop StoriesPoliticsBusinessEconomyTechnologyInternationalEnvironmentScienceSportsHealthEducationEntertainmentLifestyleCultureCrime & LawTravel & TourismFood & RecipesFact CheckReligion
POLITICS
Positive Sentiment

Trump Orders Federal Rescheduling To Expand Cannabis Research

Read, Watch or Listen

Trump Orders Federal Rescheduling To Expand Cannabis Research
Media Bias Meter
Sources: 9
Center 100%
Sources: 9

Washington, President Donald Trump signed an executive order Thursday directing federal agencies to expedite reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act. Officials said the change recognizes medical use and will ease research barriers, banking access, and tax treatment such as 280E relief. State researchers and attorneys general offered mixed reactions, noting potential benefits for clinical studies and continued regulatory constraints, heightened federal oversight. Cannabis companies and payment firms welcomed the move, citing improved operations and investment prospects. The executive order does not legalize recreational use. Based on 6 articles reviewed and supporting research.

Prepared by Lauren Mitchell and reviewed by editorial team.

Timeline of Events

  • November 12, 2025 — Federal clarification issued on hemp-derived intoxicants.
  • December 18, 2025 — President signs executive order directing expedited rescheduling to Schedule III.
  • December 18, 2025 — Corporations (FLUENT, POSaBIT) issue supportive press releases.
  • December 18–19, 2025 — Local researchers and state officials comment on research opportunities and regulatory limits.
  • Post-signature — Attorneys general and legal actors indicate potential challenges and extended administrative procedure.
Media Bias
Articles Published:
6
Right Leaning:
0
Left Leaning:
0
Neutral:
6

Who Benefited

Licensed cannabis companies, payment processors, investors, medical researchers, patients seeking clinical trials, and banks are likely to see reduced regulatory barriers, improved access to financial services, and potential tax relief following the rescheduling directive.

Who Impacted

Some state officials, law enforcement stakeholders, and opponents of cannabis liberalization may face increased pressure and legal challenges as federal guidance shifts, prompting debates over public health, enforcement, and youth access.

Media Bias
Articles Published:
6
Right Leaning:
0
Left Leaning:
0
Neutral:
6
Distribution:
Left 0%, Center 100%, Right 0%
Who Benefited

Licensed cannabis companies, payment processors, investors, medical researchers, patients seeking clinical trials, and banks are likely to see reduced regulatory barriers, improved access to financial services, and potential tax relief following the rescheduling directive.

Who Impacted

Some state officials, law enforcement stakeholders, and opponents of cannabis liberalization may face increased pressure and legal challenges as federal guidance shifts, prompting debates over public health, enforcement, and youth access.

Coverage of Story:

From Left

No left-leaning sources found for this story.

From Right

No right-leaning sources found for this story.

Related News

Comments

JQJO App
Get JQJO App
Read news faster on our app
GET